The effects of pioglitazone on postprandial glucose and lipid metabolism and vascular function

The effects of pioglitazone on postprandial glucose and lipid metabolism and vascular function - The effects of pioglitazone on postprandial metabolism and vascular function

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002772

Enrollment

Registered

2009-11-17

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Oral administration of Pioglitazone (30mg) for about six months or more.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Patients with poorly controled type 2 diabetes mellitus Patients under insulin therapy Patients with frequent arrythmia Patients with renal or liver dysfunction Patients with malignant or collagen disease

Design outcomes

Primary

Measure	Time frame
Improvement of postprandial glucose and lipid parameters. Postprandial changes in arterial stiffness (augmentation index of radial artery) and central blood pressure.	—

Countries

Japan

Contacts

Public ContactJun-ichi Funada

NHO Ehime National Hospital The department of cardiology

089-964-2411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026